Revive Therapeutics Director Signs Manufacturing Arrangement With Vaxart
It appears that Revive Therapeutics (CSE: RVV) has a budding superstar on its board of directors. Last week, Revive’s independent director William Jackson saw his private company sign a significant manufacturing agreement with that of Vaxart Inc, a clinical stage biotech firm that is focused on develop oral tablet vaccines.
Last Thursday, Vaxart Inc (NASDAQ: VXRT) announced that it had signed a memorandum of understanding with that of Attwill Medical Solutions Steriflow, LP, (AMS) a private firm lead by William (Bill) Jackson. Under the MOU, Attwill will be a resource for lyophilization development, as well as large scale manufacturing.
The manufacturing is said to include tableting and enteric coating for Vaxart’s oral COVID-19 vaccine. The manufacturing, as per the release, will enable production of “a billion or more COVID-19 vaccine doses per year,” with Attwill dedicating its resources and equipment for scale up and commercial production of the vaccine once a formal agreement is entered into.
“We believe AMS’ experience coupled with its ability to manufacture a billion or more doses per year would be a beneficial addition to our group of CDMO partners and enable the large scale manufacturing and ultimate supply of our COVID-19 vaccine for the US, Europe and other countries in need.”Andrei Floroiu, CEO of Vaxart Inc
The announcement is significant for Revive, whom has seen Jackson serve as an independent board member since the firms qualifying transaction in January 2014. The recent announcement not only demonstrates the strength of Revive’s team, but also the significant pharmaceutical connections and relationships held by members of the executive team. As Revive heads into phase 3 clinical trials for the use of Bucillamine in the treatment of infectious diseases such as COVID-19, these relationships will continue to be a net positive for the firm.
Revive Therapeutics last traded at $0.30 on the CSE.
FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.